Novartis Ag (NVS) FCF Payout Ratio (2009 - 2026)

Novartis Ag (NVS) posted FCF Payout Ratio of 0.52 for Q2 2026, up 31.57% sequentially from 0.39 in Q2 2025, and up 31.57% YoY from 0.39 in Q2 2025.

Novartis Ag (NVS) FCF Payout Ratio (2009 - 2026) Analysis & Trends

Novartis Ag has reported FCF Payout Ratio for 15 years, with the latest figure at 0.52 in Q2 2026.

Quarterly FCF Payout Ratio rose 31.57% year-over-year to 0.52 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.68 (down 399.21% YoY) and the FY2025 annual result came in at 0.44, down 5.28% from the prior year.
FCF Payout Ratio rose to 0.52 in Q2 2026 per NVS's latest filing, from 0.39 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 2.86 in Q2 2023 and troughed at 0.99 in Q4 2024.
A 5-year average of 0.54 and a median of 0.45 in 2025 frame the typical range for FCF Payout Ratio.
The sharpest annual moves came in 2023 and 2024: FCF Payout Ratio soared 216.94% in 2023, then plunged 116.44% in 2024.
Over 5 years, FCF Payout Ratio stood at 0.9 in 2022, then soared by 216.94% to 2.86 in 2023, then slumped by 134.58% to 0.99 in 2024, then surged by 139.62% to 0.39 in 2025, then jumped by 31.57% to 0.52 in 2026.
According to Business Quant data, FCF Payout Ratio over the past three periods registered 0.52, 0.39, and 0.99 for Q2 2026, Q2 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Johnson & Johnson	653.71 Bn	632.95 Bn	17.26 Bn	0.44
2	AbbVie	469.97 Bn	463.40 Bn	12.70 Bn	0.99
3	Merck	375.96 Bn	368.82 Bn	12.21 Bn	0.48
4	Novartis Ag	304.06 Bn	296.37 Bn	11.24 Bn	0.52
5	Astrazeneca	257.78 Bn	252.88 Bn	12.86 Bn	-3.54
6	Amgen	236.52 Bn	222.53 Bn	7.24 Bn	0.39
7	Gilead Sciences	182.20 Bn	179.02 Bn	6.22 Bn	0.30
8	Pfizer	159.49 Bn	147.79 Bn	10.94 Bn	8.12
9	Gsk	106.34 Bn	102.17 Bn	8.24 Bn	-
10	Sanofi	55.19 Bn	47.81 Bn	10.79 Bn	-

Download Data